This article is more than 5 years old. Information may no longer be current.

iSTAR Medical completes Series C funding round

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

iSTAR Medical has completed 40 million euros in Series C financing to be used in the development of its MINIject device for the treatment of glaucoma, according to a press release.

Health care specialist funds LSP and Gimv led the funding round, with participation from Earlybird, BNP Paribas Fortis Private Equity, Capricorn Partners, Walloon Region Investment Fund and Belgian Federal Investment Fund.

“We are delighted to welcome LSP, Gimv, Earlybird and BNP Paribas Fortis Private Equity to iSTAR Medical, and I would like to thank our existing investors for their continued support,” Michel Lussier, iSTAR chairman of the board of directors, said in the release. “This renowned investor syndicate has a track record of supporting successful, innovative companies and is a strong endorsement of our world-leading technology for glaucoma sufferers.”

The MINIject ab interno MIGS device is designed to reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space.